Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
MT-2 vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
MT-2 is distinguished by a nonselective melanocortin agonist with tiny early human studies of pigmentation and erectile response. Unlike MT-1's SCENESSE implant, MT-2 has no FDA-approved product or indication; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
MT-2 is distinguished in the current record by a nonselective melanocortin agonist with tiny early human studies of pigmentation and erectile response. Unlike MT-1's SCENESSE implant, MT-2 has no FDA-approved product or indication. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagrilintide
MT-2: Very early human evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
MT-2: Not FDA approved. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthMT-2
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
MT-2
- Skin pigmentation
- Erectile response in men
- Sexual desire in men
- Vitiligo with narrowband UV-B — registered trial, no results
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
MT-2Not FDA approved
Not FDA approved. FDA identifies potential significant safety risks for compounded MT-2, including immunogenicity from aggregation or peptide-related impurities and serious published adverse-event reports.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
MT-2Three tiny controlled studies
One three-person pigmentation Phase 1 pilot, two ten-person placebo-controlled erectile-response crossover studies, one 2026 registered Phase 2 vitiligo trial without results, and multiple safety case reports.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
MT-2No dedicated human evidence
No controlled human weight-loss or body-composition outcome trial was located. Reduced appetite appeared as a short-term adverse effect; weight claims are primarily preclinical or anecdotal.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
MT-2No dedicated evidence
No controlled human glucose-control or diabetes-outcomes study was located.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
MT-2No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
MT-2No outcomes program
No cardiovascular outcomes program was located. Case reports describe serious systemic toxicity, renal injury or infarction, and ischemic priapism, but cannot estimate incidence.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
MT-2Historical study protocols only
Historical studies used monitored subcutaneous protocol exposures. MT-2 has no FDA-approved consumer dose, route, schedule, reconstitution method, or storage instructions.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term and repeated-use safety, risks across broader populations, and whether unregulated products match the studied compound.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
MT-2
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.